Financial Data and Key Metrics Changes - STAAR Surgical reported net sales of $39.7 million in Q2 2019, an increase of 17% compared to $33.9 million in Q2 2018 [18] - Adjusted net income for Q2 2019 was $6.5 million or $0.14 per diluted share, compared to $3.9 million or $0.09 per diluted share in the prior year [20] - Gross profit margin improved to 75.4%, up 100 basis points from 74.4% in the prior year [19] Business Line Data and Key Metrics Changes - ICL revenue grew by 26%, representing 87% of total company net sales in Q2 2019 [18] - Other product segment sales declined by 21% in the quarter [18] - ICL unit growth was 34% globally, marking the eighth consecutive quarter of double-digit growth [9] Market Data and Key Metrics Changes - In China, ICL unit growth was 48%, while Korea, Japan, and India saw growth rates of 42%, 29%, and 22% respectively [9] - The largest market for refractive procedures is China, accounting for over 24% of the 4 million global procedures annually [10] Company Strategy and Development Direction - The company aims to achieve 30% ICL unit growth and 20% revenue growth for the full year [8] - STAAR is focusing on expanding its presence in the U.S. market and enhancing partnerships with refractive surgeons [40] - The company is pursuing FDA approval for its EVO lens and has submitted a clinical trial design [13][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory in China, citing strong demand and new account openings [28] - The company anticipates stronger cash generation in the second half of 2019 compared to the first half [22] - Management highlighted the importance of building relationships with surgeons and enhancing marketing efforts in the U.S. [40] Other Important Information - The company achieved the primary endpoint in its European multi-site clinical trial for the EDOF lens for presbyopia, with 98% of implanted eyes meeting the criteria [15][16] - STAAR is planning to host an Investor Day in November 2019 to outline its strategic vision for 2020-2022 [17] Q&A Session Summary Question: Insights on growth in China and new accounts - Management noted that demand in China is significantly higher than traditional sales growth, with new accounts contributing positively to future growth [28] Question: Regulatory pathway for EVO lens - Management indicated positive discussions with the FDA and a respectful relationship, aiming for a least burdensome pathway for approval [30] Question: EDOF lens expectations and clinical data - Management stated that the timeline for EDOF lens approval is based on past experiences and the submission for presbyopic indications [36] Question: U.S. market trends and growth expectations - Management emphasized the reintroduction of the company as a premium partner to refractive surgeons and the positive reception of the Toric product [40][44] Question: Size of the trial for EVO approval - Management could not disclose specific details about the trial size and follow-up period due to confidentiality [47]

Financial Data and Key Metrics Changes - STAAR reported net sales of $32.6 million in Q1 2019, an increase of 20% over $27.1 million in the prior year period [19] - Adjusted for currency headwinds, net sales would have increased approximately 23% to $33.3 million [19] - Gross profit margin for Q1 was 74.2%, up 250 basis points from 71.7% in the prior year [20] - Net income for Q1 was $1.4 million or approximately $0.03 per diluted share, compared to $0.6 million or $0.01 per diluted share in the prior year [22] Business Line Data and Key Metrics Changes - ICL revenue grew by 31%, representing 85% of total company net sales in the quarter [19] - Other products segment sales declined by 19% in the quarter [19] - Operating income was approximately $1.6 million in Q1, compared to $0.8 million in the prior year [21] Market Data and Key Metrics Changes - ICL unit growth was 39% globally, significantly above the 5% to 6% growth reported in the ophthalmic sector [8] - ICL sales growth in Asia was exceptional, with Japan growing 94%, Korea 50%, China 49%, and India 26% [9] - North America grew by 15%, with the U.S. at 24% offsetting a decline in Canada [9] Company Strategy and Development Direction - The company aims to double ICL unit growth again by the end of 2020, focusing on a more aggressive strategic plan [28] - New strategic cooperation agreements were announced to partner closely with refractive surgeons [10] - The company is expanding its manufacturing capacity and investing in clean rooms for new product lines [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustained meaningful growth for ICL globally, with a target market share of 20% to 30% for myopia correction [11] - The company is optimistic about the upcoming CE Mark application for the presbyopia lens and ongoing discussions with the FDA regarding the EVO ICL family [12] - Management expects Q2 and Q3 to be the highest projected quarters of the year, particularly in China [34] Other Important Information - The company celebrated the milestone of 1 million ICLs implanted, indicating strong market acceptance [10] - Cash, cash equivalents, and restricted cash totaled $102.2 million as of March 29, 2019 [23] Q&A Session Summary Question: Confirmation of ICL unit growth doubling - Management confirmed that they hope to double ICL unit growth again by the end of 2020 and emphasized a more aggressive strategic plan [28] Question: Details on U.S. alliances and implications of new guidelines - Management explained that U.S. alliances involve marketing support and surgeon training, and the new guidelines in Germany and Japan expand the diopter range for ICLs [30] Question: Growth rate in China and inventory management - Management clarified that the perceived deceleration in growth is due to prudent inventory management, with expectations for strong Q2 and Q3 performance in China [34] Question: Update on Switzerland facility - Management stated that the Switzerland facility will be reopened as a premium manufacturing site for ICL lenses, with an expected capital outlay of about $3 million [36][37] Question: Expectations for sales and marketing spending - Management anticipates an increase in sales and marketing spending beginning in Q2, especially with upcoming trade shows [55]

STAAR Surgical Company. (NASDAQ:STAA) Q4 2018 Results Earnings Conference Call February 21, 2019 4:30 PM ET Company Participants Brian Moore - IR, EVC Group Caren Mason - President and CEO Deborah Andrews - CFO Conference Call Participants Jason Mills - Canaccord Genuity Andrew Brackmann - William Blair Chris Cooley - Stephens Jim Sidoti - Sidoti & Company Operator Good day, ladies and gentlemen. Thank you for standing by. Welcome to the STAAR Surgical Fourth Quarter and Full Year 2018 Financial Results Con ...